Interferon beta: Phase IIa started

AstraZeneca began the double-blind, placebo-controlled, international Phase IIa INEXAS trial to evaluate 24 ug inhaled AZD9412 once daily for 14 days in 220 patients. INEXAS will enroll patients who r...